Current perspectives on FTY720

被引：22

作者：

Martini, Sebastian

Peters, Harm

Boehler, Torsten

Budde, Klemens

机构：

[1] Univ Med Berlin, Charite, Dept Nephrol, D-10117 Berlin, Germany

[2] CHU Rangueil, INSERM, Inst Louis Bugnard, U466, F-31054 Toulouse, France

来源：

EXPERT OPINION ON INVESTIGATIONAL DRUGS | 2007年 / 16卷 / 04期

关键词：

fingolimod; FTY; FTY720; multiple sclerosis; renal transplantation; sphingosine-1-phosphate;

D O I：

10.1517/13543784.16.4.505

中图分类号：

R9 [药学];

学科分类号：

1007 ;

摘要：

The search for effective immunosuppressants with fewer side effects continues not only for transplantation, but also for autoimmune diseases. With a novel mechanism of action (sphingosine-1 receptor modulation), oral FTY720 (fingolimod) has the potential to address this need. FTY720 has been preclinically tested with promising results in transplantation and autoimmune disease models. Phase I studies explored the pharmacokinetics and pharmacodynamics of this novel therapeutic concept. Recently, the surprising results of two sister Phase III studies in de novo renal transplant patients, as well as a Phase II study in patients with relapsing multiple sclerosis, were published. This review discusses these findings as well as their implications for the future of sphingosine-1 receptor modulation.

引用

收藏

页码：505 / 518

页数：14

相关论文

共 93 条

[51] Lymphocyte egress from thymus and peripheral lymphoid organs is dependent on S1P receptor 1 [J].

Matloubian, M ;

Lo, CG ;

Cinamon, G ;

Lesneski, MJ ;

Xu, Y ;

Brinkmann, V ;

Allende, ML ;

Proia, RL ;

Cyster, JG .

NATURE, 2004, 427 (6972) :355-360

[52] FTY720/cyclosporine regimens in de novo renal transplantation:: A 1-year dose-finding study [J].

Mulgaonkar, S. ;

Tedesco, H. ;

Oppenheimer, F. ;

Walker, R. ;

Kunzendorf, U. ;

Russ, G. ;

Knoflach, A. ;

Patel, Y. ;

Ferguson, R. .

AMERICAN JOURNAL OF TRANSPLANTATION, 2006, 6 (08) :1848-1857

[53] T cell selective apoptosis by a novel immunosuppressant, FTY720, is closely regulated with Bcl-2 [J].

Nagahara, Y ;

Ikekita, M ;

Shinomiya, T .

BRITISH JOURNAL OF PHARMACOLOGY, 2002, 137 (07) :953-962

[54]

Nishikawa K, 2001, Clin Transpl, P247

[55] FTY720, a synthetic sphingosine 1 phosphate analogue, inhibits development of atherosclerosis in low-density lipoprotein receptor-deficient mice [J].

Nofer, Jerzy-Roch ;

Bot, Martine ;

Brodde, Martin ;

Taylor, Paul J. ;

Salm, Paul ;

Brinkmann, Volker ;

van Berkel, Theo ;

Assmann, Gerd ;

Biessen, Erik A. L. .

CIRCULATION, 2007, 115 (04) :501-508

[56] Atheroprotective effects of high-density lipoprotein-associated lysosphingolipids [J].

Nofer, JR ;

Assmann, G .

TRENDS IN CARDIOVASCULAR MEDICINE, 2005, 15 (07) :265-271

[57] HDL induces NO-dependent vasorelaxation via the lysophospholipid receptor S1P3 [J].

Nofer, JR ;

van der Giet, M ;

Tölle, M ;

Wolinska, I ;

Lipinski, KVW ;

Baba, HA ;

Tietge, UJ ;

Gödecke, A ;

Ishii, I ;

Kleuser, B ;

Schäfers, M ;

Fobker, M ;

Zidek, W ;

Assmann, G ;

Chun, J ;

Levkau, B .

JOURNAL OF CLINICAL INVESTIGATION, 2004, 113 (04) :569-581

[58]

NOVGORODOV AS, 2007, IN PRESS FASEB J

[59] Delayed graft function: Risk factors and implications for renal allograft survival [J].

Ojo, AO ;

Wolfe, RA ;

Held, PJ ;

Port, FK ;

Schmouder, RL .

TRANSPLANTATION, 1997, 63 (07) :968-974

[60]

Okazaki H, 2002, J RHEUMATOL, V29, P707

← 1 2 3 4 5 6 7 8 9 10 →